Technology | 2009.11.12
EnteroMedics Announces Preliminary Results from Detailed Review of EMPOWER Study
ST. PAUL, Minn.--(BUSINESS WIRE)--EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced preliminary findings from its ongoing detailed review of its EMPOWER™ study, a randomized, double-blind, controlled pivotal study designed to evaluate the safety and efficacy of the Maestro® System in the treatment of obesity. On October 2, 2009, the Company announced that the study di
For more information, please visit
http://www.businesswire.com/news/home/20091112005335/en
Follow us on
Instagram is adding automatic in-app text translation - The Verge views: 1553
Instagram is adding automatic in-app text translation - The Verge views: 1506